Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
Indianapolis-based Eli Lilly and Co. is suing Sun Pharmaceutical Industries Ltd. of India to stop Sun from selling a generic version of its hyper-disorder drug Strattera.
Lilly, which filed the suit in Detroit on Sept. 20, said it would be “irreparably harmed” if the generic wasn’t stopped, according to Bloomberg.
Sun’s application to the U.S. Food and Drug Administration says Lilly’s patent is invalid, unenforceable or uninfringed.
Strattera treats attention deficit/hyperactivity disorder, and generated $282 million in sales in the first half of this year for Lilly.
Please enable JavaScript to view this content.